Physician profile
Rakesh Kumar Sharma
NPI 1508942574
$5,887.16
in general payments reported to CMS, 2019-2025
29 companies · $610 in 2025
The $610 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $623 · 2020: $712 · 2021: $759 · 2022: $895 · 2023: $1,232 · 2024: $1,056 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,888 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,887.55 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $781.53 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Abbvie INC. | $704.10 | 2021-2025 | Teflaro, Avycaz, Dalvance |
| Janssen Pharmaceuticals, INC | $609.59 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $490.00 | 2021-2025 | Apollo Esg System, Avvigo Guidance System |
| Shionogi INC | $457.46 | 2021-2025 | Fetroja |
| Pfizer INC. | $441.52 | 2019-2024 | |
| Genzyme Corporation | $371.19 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $368.66 | 2020-2024 | Andexxa |
| Novartis Pharmaceuticals Corporation | $174.01 | 2019-2021 | |
| La Jolla Pharmaceutical Company | $166.94 | 2021-2024 | Xerava |
| Melinta Therapeutics, LLC | $162.28 | 2021-2024 | Orbactiv, Kimyrsa, Rezzayo |
| Chiesi USA, INC. | $157.99 | 2023-2024 | Cleviprex, Kengreal |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $117.41 | 2019 | |
| Novo Nordisk INC | $108.98 | 2020-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $82.64 | 2020-2021 | |
| Exact Sciences Corporation | $80.34 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $79.33 | 2020 | |
| Lilly USA, LLC | $75.41 | 2022 | |
| Abbott Laboratories | $72.87 | 2020 | |
| Idorsia Pharmaceuticals US INC | $67.87 | 2023 | Quviviq |
| Cumberland Pharmaceuticals, INC. | $48.10 | 2022-2025 | Caldolor |
| Shield Therapeutics INC | $25.96 | 2024 | |
| Gilead Sciences, INC. | $24.92 | 2023 | |
| Glaxosmithkline, LLC. | $21.51 | 2021 | |
| Paratek Pharmaceuticals, INC. | $19.92 | 2021 | |
| Amgen INC. | $18.38 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $17.38 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.87 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rakesh Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.